The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Human epidermal growth factor receptor 2 (HER2 or ErbB2) can be overexpressed, amplified and/or mutated in malignant tumors, and is a candidate for therapeutic targeting. However, molecular associations and clinical significances of these alterations were controversial in lung cancer. In this study,...
Main Authors: | Eun Kyung Kim, Kyung A Kim, Chang Young Lee, Hyo Sup Shim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5287480?pdf=render |
Similar Items
-
Expression of HER-2/neu in lung Adenocarcinoma
by: Kuan-Fu Lin, et al.
Published: (2010) -
Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
by: Yoon Jin Cha, et al.
Published: (2014-01-01) -
Adenocarcinoma of the minor salivary gland with concurrent MAML2 and EWSR1 alterations
by: Sangjoon Choi, et al.
Published: (2021-03-01) -
Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
by: Doo-Yi Oh, et al.
Published: (2017-08-01) -
Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
by: Hongsik Kim, et al.
Published: (2019-09-01)